Development of point-of-care product for alzheimer's disease

• Main Author: Oktavina, Shellia
• Other Authors: Li Hoi Yeung
• Format: Final Year Project
• Language: English
• Published: Nanyang Technological University 2022
• Subjects: Science::Biological sciences
• Online Access: https://hdl.handle.net/10356/163584
• Institution: Nanyang Technological University

Alzheimer’s disease (AD) is a neurodegenerative disease affecting over 55 million people worldwide, with approximately 60% undiagnosed cases. Early detection is critical in allowing early intervention that may significantly impact patients’ quality of life and reduce overall AD-related cost. Current AD diagnosis methods involve invasive procedure, high-cost, and specific registered-laboratories. Detecting trace amount of AD biomarker from less-invasive standpoint using plasma specimen has remained a challenge, but it could provide earlier and easier AD screening if made possible. This suggests the need of a point-of-care (POC) product that allows better access to AD detection in primary care settings. To achieve this, this study aimed to develop a POC product to detect a well-studied biomarker, Amyloid Beta peptide-42 (Aβ42), in plasma using Instant NanoBiosensors Fiber-Optic Particle Plasmon Resonance (INB FOPPR) system. The binding analysis performed using INB FOPPR system has shown comparable kinetics results with other systems, and the presence of Aβ42 binding detected brings great potential for AD early detection. With further optimisation, INB FOPPR system will serve as a promising POC product to address unmet needs of better access to AD detection, allowing effective screening for AD patients in primary care settings with its rapid analysis and portable design.